Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo for inhalation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    659 result(s) found for: placebo for inhalation. Displaying page 31 of 33.
    «« First « Previous 25  26  27  28  29  30  31  32  33  Next»
    EudraCT Number: 2012-005184-27 Sponsor Protocol Number: 49095397OPD2001 Start Date*: 2013-08-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ-49095397 (RV568) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease.
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) HU (Completed) CZ (Completed) NL (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-005094-54 Sponsor Protocol Number: TPI ASM8-205 Start Date*: 2008-01-17
    Sponsor Name:Topigen Pharmaceuticals Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 14-DAY INHALED TPI ASM8 IN SUBJECTS WITH ASTHMA
    Medical condition: allergic asthma and allergen-induced asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000611-14 Sponsor Protocol Number: 201314 Start Date*: 2014-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive P...
    Medical condition: in subjects with Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022437-28 Sponsor Protocol Number: 40929837ASH2001 Start Date*: 2010-11-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model
    Medical condition: JNJ-40929837 is being developed for the treatment of asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003962-16 Sponsor Protocol Number: D3540C00005 Start Date*: 2007-11-27
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic O...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001051-19 Sponsor Protocol Number: CQAB149B2217 Start Date*: 2007-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic...
    Medical condition: COPD (chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000529-19 Sponsor Protocol Number: 201211 Start Date*: 2014-05-22
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD
    Medical condition: Subjects with COPD
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005548-32 Sponsor Protocol Number: CCD-06001AA1-01 Start Date*: 2016-10-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 24-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 4 DOSES OF CHF 6001 DPI IN P...
    Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-000188-15 Sponsor Protocol Number: AL1402ac Start Date*: 2017-01-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o...
    Medical condition: allergic bronchial asthma and allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039097 Rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) LT (Completed) DE (Completed) ES (Completed) LV (Completed) AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002341-42 Sponsor Protocol Number: CCSJ117A12201E1 Start Date*: 2021-10-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) DE (Completed) BE (Completed) BG (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002341-12 Sponsor Protocol Number: DEB-EPI-206 Start Date*: 2005-02-14
    Sponsor Name:Debiopharm SA
    Full Title: Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011762 PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005984-27 Sponsor Protocol Number: 0476-332 Start Date*: 2006-03-23
    Sponsor Name:Suomen MSD Oy
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Ast...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SI (Completed) ES (Completed) LT (Completed) BE (Completed) EE (Completed) HU (Completed) PT (Completed) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001251-40 Sponsor Protocol Number: MEA115588 Start Date*: 2012-10-16
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon...
    Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000764-30 Sponsor Protocol Number: HOT-LOCO Start Date*: 2021-07-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Hyperbaric Oxygen for Treatment of Long COVID syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial
    Medical condition: Long COVID, post-acute COVID-19 Syndrome, post COVID-19 Syndrome (ICD-10 U09.0)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.1 10021881 - Infections and infestations 10057244 Post viral fatigue syndrome PT
    20.0 10007541 - Cardiac disorders 10063080 Postural orthostatic tachycardia syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016690-15 Sponsor Protocol Number: AC4113589 Start Date*: 2010-02-12
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001578-25 Sponsor Protocol Number: P04334 Start Date*: 2007-02-12
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002239-44 Sponsor Protocol Number: 200110 Start Date*: 2013-08-20
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -St...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001577-13 Sponsor Protocol Number: P04073 Start Date*: 2007-02-12
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002069-32 Sponsor Protocol Number: RPL554-CO-302 Start Date*: 2020-11-25
    Sponsor Name:Verona Pharma PLC
    Full Title: A Phase III Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary D...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005080-28 Sponsor Protocol Number: BY217/M2-127 Start Date*: 2006-04-04
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of roflumilast in COPD patients treated with salmeterol. A 24 week, double blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 25  26  27  28  29  30  31  32  33  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 08:58:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA